Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

68 BIMATOPROST
BIMATOPROST
Trade name: Lumigan (Allergan)
Indications: Open-angle glaucoma, ocular hypertension
Category: Prostaglandin analog
Half-life: 45 minutes
Reactions
Skin
Keratoses
(2006): Kothari MT+, Indian J Ophthalmol 54(1), 47
Photoallergic reaction
(2003): Packer M+, J Cataract Refract Surg 29(11), 2242
Hair
Hair – hirsutism (1–5%)
Hair – hypertrichosis
(2004): Hart J+, Am J Ophthalmol 137(4), 756 (malar)
Eyes
Blepharitis (3–10%)
Conjunctival hyperemia (>10%)
(2006): Brittain CJ+, Adv Ther 23(1), 68
(2005): Arcieri ES+, Arch Ophthalmol 123(2), 186
(2005): Chen J+, Cardiovasc Drug Rev 23(3), 231
(2005): Konstas AG+, Ophthalmology 112(2), 262
(2005): Wanichwecha-Rungruang B+, J Med Assoc Thai
88(9), 1228 (20%)
(2004): Leal BC+, Am J Ophthalmol 138(2), 310
(2003): Abelson MB+, Adv Ther 20(1), 1
(2003): Agarwal HC+, JOculPharmacol19(2), 105 (32%)
(2003): Gandolfi SA+, Ophthalmology 110(3), 609
(2003): Noecker RS+, Am J Ophthalmol 135(1), 55
(2003): Stewart WC+, Am J Ophthalmol 135(3), 314
(2002): Eisenberg DL+, Surv Ophthalmol 47 Suppl 1, S105
(2002): Higginbotham EJ+, Arch Ophthalmol 120(10), 1286
(2001): DuBiner H+, Surv Ophthalmol 45(Suppl 4), S353–60
(2001): Gandolfi S+, Adv Ther 18(3), 110
(2001): Laibovitz RA+, Arch Ophthalmol 119(7), 994
(2001): Sherwood M+, Surv Ophthalmol 45(Suppl 4), S361–8
Eyelashes – hypertrichosis (>10%)
(2005): Modschiedler K+, J Dtsch Dermatol Ges 3(4), 276
(2004): Jaffe P, Columbia, SC (from Internet) (observation)
(2004): Tosti A+, JAmAcadDermatol51(5), S149
(2003): Herndon LW+, Am J Ophthalmol 135(5), 713
(2003): Noecker RS+, Am J Ophthalmol 135(1), 55
(2003): Whitcup SM+, Br J Ophthalmol 87(1), 57
(2002): Eisenberg DL+, Surv Ophthalmol 47(Suppl 1), S105
Eyelashes – pigmentation
(2005): Modschiedler K+, J Dtsch Dermatol Ges 3(4), 276
(2004): Jaffe P, Columbia, SC (from Internet) (observation)
Eyelid erythema (3–10%)
Eyelid irritation (3–10%)
Eyelid pain (3–10%)
Eyelid pigmentation (3–10%)
(2005): Galloway GD+, Arch Ophthalmol 123(11), 1609
(2005): Kapur R+, Arch Ophthalmol 123(11), 1541
(2003): Herndon LW+, Am J Ophthalmol 135(5), 713
Eyelid xerosis (3–10%)
Macular edema
(2006): Kruse P+, Klin Monatsbl Augenheilkd 223(6), 534
Ocular edema
(2005): Arcieri ES+, Arch Ophthalmol 123(2), 186
Ocular pain
(2003): Packer M+, J Cataract Refract Surg 29(11), 2242
Ocular pigmentation (1–3%)
(2004): Sodhi PK+, Am J Ophthalmol 137(4), 783
(2003): Herndon LW+, Am J Ophthalmol 135(5), 713
(2002): Novack GD+, JAmGeriatrSoc50(5), 956
(2002): Stjernschantz JW+, Surv Ophthalmol 47(Suppl 1), S162
(2001): Sherwood M+, Surv Ophthalmol 45(Suppl 4), S361–8
(1.1%)
Ocular pruritus (>10%)
Uveitis
(2005): Cano Parra J+, Arch Soc Esp Oftalmol 80(3), 137
(2003): Packer M+, J Cataract Refract Surg 29(11), 2242
Other
Upper respiratory infection (10%)
BIPERIDEN
Trade names: Akineton (Par); Biperen; Bipiden; Dekinet;
Desiperiden; Dyskinon
Indications: Parkinsonism
Category: Anticholinergic; Muscarinic antagonist
Half-life: 18–24 hours
Clinically important, potentially hazardous interactions
with: anticholinergics
Reactions
Skin
Dermatitis
(1995): Torinuki W, Tohoku J Exp Med 176, 249
Diaphoresis
(2001): Richardson C+, Am J Psychiatry 158(8), 1329
Exanthems
Rash (sic)
Urticaria
Mucosal
Glossodynia
Stomatodynia
Xerostomia
BISACODYL
Trade names: Apo-Bisacodyl; Biscolax; Carter’s Little Pills;
Dacodyl; Dulcagen; Dulcolan; Dulcolax (Boehringer Ingelheim);
Fleet Laxative; Laxit
Indications: Constipation
Category: Stimulant laxative
Half-life: N/A
Onset of action: 6–10 hours
Clinically important, potentially hazardous interactions
with: digoxin
Reactions
Skin
Diaphoresis
Exanthems
Fixed eruption
(1997): Burrow WH, Jackson, MS (from Internet) (observation)
Urticaria